A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)

L. Shen; J. A. Ajani; S. B. Kim; E. Van Cutsem; B. Guo; J. Song; V. Paton; K. Kato

doi:10.1093/annonc/mdy282.158

A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)

L. Shen, J. A. Ajani, S. B. Kim, E. Van Cutsem, B. Guo, J. Song, V. Paton, K. Kato

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	viii264
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy282.158
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy282.158

Cite this

Shen, L., Ajani, J. A., Kim, S. B., Van Cutsem, E., Guo, B., Song, J., Paton, V., & Kato, K. (2018). A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii264. https://doi.org/10.1093/annonc/mdy282.158

A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC). / Shen, L.; Ajani, J. A.; Kim, S. B. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii264.

Research output: Contribution to journal › Article › peer-review

Shen, L, Ajani, JA, Kim, SB, Van Cutsem, E, Guo, B, Song, J, Paton, V & Kato, K 2018, 'A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii264. https://doi.org/10.1093/annonc/mdy282.158

Shen L, Ajani JA, Kim SB, Van Cutsem E, Guo B, Song J et al. A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii264. doi: 10.1093/annonc/mdy282.158

@article{c85f2b04bcd94cb088cebea999f3ab42,

title = "A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)",

author = "L. Shen and Ajani, {J. A.} and Kim, {S. B.} and {Van Cutsem}, E. and B. Guo and J. Song and V. Paton and K. Kato",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy282.158",

language = "English (US)",

volume = "29",

pages = "viii264",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)

AU - Shen, L.

AU - Ajani, J. A.

AU - Kim, S. B.

AU - Van Cutsem, E.

AU - Guo, B.

AU - Song, J.

AU - Paton, V.

AU - Kato, K.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081082710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081082710&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy282.158

DO - 10.1093/annonc/mdy282.158

M3 - Article

C2 - 32136601

SN - 0923-7534

VL - 29

SP - viii264

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this